A report from the PCM4EU @ MPNE-Workshop that took place in Brussel end of April 2023, is now available.
Opportunity to collaborate with a European patient organization and the patients and physicians communities:
Why DRUP-like clinical trials (DLCTs) are relevant for the European Cancer Patient Community?
DLCTs are relevant because they offer an opportunity to many patients with advanced cancer who have no other treatment solution:
Several similar initiatives operate together in Europe and provide an important framework for medical decision-making and accessible databases of molecular tests. DLCTs therefore aim at wider access to clinical trials and better care and solutions for individual patients and MTBs play a fundamental role in this process. However, their implementation requires addressing several economic, political and technical challenges.
Establishing international DLCT cohorts/cross-border access to DLCTs:
An example discussed in the workshop, illustrates the difficulty and rarity of transnational care pathways even between border countries. The demonstration highlighted two important keypoints:
However, the following challenges and problems were identified :
Access to Molecular Tumour Boards
Securing drugs to new cohorts in DLCTs is challenging as it depends on the evidence put forward to the pharmaceutical companies. One way of doing this is to share the results of molecular databases with the pharmaceutical industry. Moreover, additional tests are necessary before treatment and equal access to these drugs and to MTBs should be considered.
Several problems were identified, including:
The workshop worked on the following themes:
What is next?
The results of the working groups are now being compiled and will lead to another meeting to work on the causes identified through the Ishikawa method. The workshops will continue to include different stakeholders in order to enrich the reflection. These reflections will also be shared within the PCM4EU consortium to contribute to the implementation of precision medicine in Europe.
Missed any updates or just exploring? Take a look through our archive!
Combining expertise across boarders to implement equitable and sustainable precision cancer medicine
The PCM4EU Spring Academy - Upcoming event in Porto, Portugal, April 2024.
New podcast episodes focusing on cross-boarder access to clinical trials available.